Navigation Links
Protein predicts Gleevec resistance in gastrointestinal tumors

Excess amounts of a protein called IGF-1R in patients with gastrointestinal stromal tumors (GISTs) could indicate that the patient would be less responsive to the drug imatinib mesylate (known as Gleevec), according to Andrew K. Godwin, Ph.D., a researcher at the Fox Chase Cancer Center in Philadelphia. Preliminary studies have shown that GIST cells, especially Gleevec-resistant cells, might respond well to agents in development for treatment-resistant breast cancer, a form of breast cancer also marked by excessive production of the IGF-1R protein. IGF-1R could also serve as a marker to identify this subset of GIST patients before therapy begins, when alternative treatments would be most effective, the researcher says.

Godwin presents his findings at the 2008 Annual Meeting of the American Society of Clinical Oncology, held May 30 through June 3 in Chicago.

A small percentage of adult gastrointestinal stromal tumors and most pediatric cases are often less responsive to Gleevec, says Godwin, Director of Fox Chase's Clinical Molecular Genetics Laboratory. We have found that tumors in many of these cases coincide with an overabundance of the IGF-1R protein.

In most occurrences, GISTs develop through a mutation in the genes c-KIT or PDGFRα, both of which are targets of Gleevec. GISTs without those mutations, known as wild type, as well as pediatric GISTs, do not often respond well to treatment with Gleevec.

The Fox Chase researchers found that, when compared to mutant GISTs, the DNA of wild type and pediatric GISTs exhibited more copies of the IGF1R gene. These tumors also produced many more copies of the IGF-1R protein, which serves to promote cell survival, proliferation and growth in normal cells. In tumors, an excess of IGF-1R allows cancer cells to grow out of control, breaking the normal control mechanisms that are an inherent part of cell function. In the laboratory, the researchers found that drugs that decrease IGF-1R activity induced the death of tumor cells.

According to Godwin and his colleagues, their studies are the first to reveal that the development of wild type GISTs could be related to abnormal expression of IGF-1R.

IGF-1R overproduction seems to be a common factor in a number of different cancers, and there are several IGF-1R-targeted therapeutic agents in development and in clinical trials that might also be effective against GISTs, Godwin says. As is often the case with targeted therapies, we need to find the right patient for the drug as much as we need to find the right drug for the disease.

Godwin and his colleagues will soon publish the full results of their studies and have begun investigating the possibility of testing for IGF-1R in clinical trials at Fox Chase.


Contact: Greg Lester
Fox Chase Cancer Center

Related medicine news :

1. Carnegie Mellon engineering researchers automate analysis of protein patterns
2. Virus mimics human protein to hijack cell division machinery
3. Naturally-occuring protein may be effective in limiting heart attack injury and restoring function
4. Scientists identify interacting proteins key to melanoma development, treatment
5. Double duty: Loss of protective heart failure protein causes high blood pressure
6. Protein May Trigger Colon Cancer
7. Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk
8. First atomic-level look at a protein that causes brain disease
9. OHSU Cancer Institute researcher identifies protein that helps predict prostate cancer survival
10. Detour(R) Unveils Snack Size Protein Bar
11. Genome analysis reveals new protein associated with breast cancer progression
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions ... SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of ... SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment ... itself for not only fulfilling the needs of advisers and clients but going ... price and providing top-tier customer service. However, there's always room for improvement, which ...
(Date:11/27/2015)... ... 2015 , ... CBD College is proud to announce that on ... accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join this ... colleges and universities in the state of California make the cut. CBD College is ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Dr. ... Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., ... observed that both STEMI and Sepsis conditions present in similar ways and require time-critical ...
(Date:11/27/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class ... (Long Term Support) into its Q-Suite 5.10 product line. , Making the change ... version of Asterisk that will receive not only security fixes, but feature and ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
(Date:11/25/2015)... , Nov. 25, 2015 ... the addition of the "Global Brain ... their offering. --> ) ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/25/2015)... WILMINGTON, N.C. , Nov. 25, 2015 /PRNewswire/ ... announces the planned investment of at least $15.8 ... in Wilmington, NC . The ... services capacity to meet the growing demands of ... Wilmington site expansion will provide up ...
Breaking Medicine Technology: